200 related articles for article (PubMed ID: 22040995)
1. [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
Shu LL; Jiang QL; Meng FY; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1314-8. PubMed ID: 22040995
[TBL] [Abstract][Full Text] [Related]
2. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Ault P; Kantarjian H; Welch MA; Giles F; Rios MB; Cortes J
Leuk Res; 2004 Jun; 28(6):613-8. PubMed ID: 15120938
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate induced immune thrombocytopenia.
Rajappa S; Varadpande L; Paul TR; Digumarti R
Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
[No Abstract] [Full Text] [Related]
5. Long-term imatinib therapy promotes bone formation in CML patients.
Fitter S; Dewar AL; Kostakis P; To LB; Hughes TP; Roberts MM; Lynch K; Vernon-Roberts B; Zannettino AC
Blood; 2008 Mar; 111(5):2538-47. PubMed ID: 18042796
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients].
Jiang Q; Chen S; Jiang B; Jiang H; Lu Y; Huang X; Lu D
Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 35(2):136-40. PubMed ID: 12920827
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
8. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
[TBL] [Abstract][Full Text] [Related]
9. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
10. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
[TBL] [Abstract][Full Text] [Related]
11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
12. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
[No Abstract] [Full Text] [Related]
13. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
Govind Babu K; Attili VS; Bapsy PP; Anupama G
Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337
[TBL] [Abstract][Full Text] [Related]
14. [Imatinib in treatment of thrombocythemia and other myeloproliferative diseases].
Shu LL; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1507-12. PubMed ID: 23257463
[TBL] [Abstract][Full Text] [Related]
15. Subdural hematomas during CML therapy with imatinib mesylate.
Song KW; Rifkind J; Al-Beirouti B; Yee K; McCrae J; Messner HA; Keating A; Lipton JH
Leuk Lymphoma; 2004 Aug; 45(8):1633-6. PubMed ID: 15370217
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
17. Imatinib for chronic myeloid leukaemia: a NICE mess.
Lim D; Muir J
Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
[No Abstract] [Full Text] [Related]
18. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
19. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
[TBL] [Abstract][Full Text] [Related]
20. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
